KBI Biopharma, Inc., a JSR Life Sciences company and global contract development and manufacturing organization (CDMO), has announced a strategic collaboration with Infinimmune, Inc., a biotechnology company focused on human-first antibody discovery and design. The partnership aims to advance the manufacturing of Infinimmune’s lead therapeutic candidate, IFX-101, a human monoclonal antibody targeting atopic dermatitis. IFX-101 is designed to offer superior efficacy and longer dosing intervals, potentially improving patient quality of life by reducing treatment frequency. Infinimmune’s approach leverages antibodies directly sourced from the human immune system, bypassing traditional engineering methods. The company’s proprietary GLIMPSE™ platform—a protein language model trained exclusively on native human antibody sequences—analyzes millions of natural immune responses to identify evolution-optimized antibody structures with enhanced biological properties. This foundation, combined with Infinimmune’s Anthrobody® technology, creates a differentiated platform in the biologics space. Wyatt McDonnell, Ph.D., CEO and Co-Founder of Infinimmune, highlighted the significance of the collaboration. “By integrating our human-first discovery platforms with KBI’s development and manufacturing expertise, we are accelerating our path toward clinical trials. Our mission is to deliver more effective, convenient treatments by harnessing the power of the human immune system, and this partnership is a critical step forward.” Katie Edgar, Chief Business Officer at KBI Biopharma, emphasized the synergy between the two organizations. “We are proud to support Infinimmune’s innovative approach to antibody development. This collaboration brings together cutting-edge discovery with KBI’s proven capabilities in biologics manufacturing, enabling faster and more efficient progress from concept to clinic.” The IFX-101 program is currently being developed at KBI’s Cell Line Development Center of Excellence in Geneva, Switzerland, utilizing KBI’s advanced SUREmAb™ platform powered by Selexis. This platform enables rapid, high-yield monoclonal antibody development and manufacturing under cGMP standards. Infinimmune is building a pipeline of novel antibody therapeutics and collaborating with pharmaceutical companies to strengthen their portfolios and expand access to new treatments. The company’s mission centers on creating safer, more effective biologics derived from natural human immune responses. KBI Biopharma, with operations across six global locations in Europe and the United States, provides end-to-end services for drug development and manufacturing. The company supports over 170 drug candidates in preclinical and clinical stages and produces ten commercial products. With a strong foundation in mammalian and microbial cell line development, KBI continues to drive innovation in biologics manufacturing and accelerate the delivery of life-changing therapies to patients worldwide.